| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Minireview
Interaction between epidermal growth factor receptor– and cyclooxygenase 2–mediated pathways and its implications for the chemoprevention of head and neck cancer
1 Department of Hematology/Oncology, Winship Cancer Institute, Emory University and 2 Quest Diagnostics, Atlanta, Georgia
Requests for reprints: Zhuo (Georgia) Chen, Department of Hematology/Oncology, Winship Cancer Institute, Emory University, Room 3086, 1365-C Clifton Road, Atlanta, GA 30322. E-mail: georgia_chen{at}emoryhealthcare.org
Head and neck squamous cell carcinoma is a well-known model for chemoprevention studies because of its field cancerization effect, its multistep carcinogenesis process, and the easy accessibility of biopsies to target lesions. With new understandings of head and neck carcinogenesis and the development of molecular targeted therapy, chemoprevention trials for head and neck squamous cell carcinoma have been rapidly updated. Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are gaining significant attention as potential chemopreventive agents. Both COX-2 and EGFR are involved in head and neck carcinogenesis. Targeting COX-2 and EGFR separately has shown promising antitumor activity. Recently, combinations of COX-2 and EGFR tyrosine kinase inhibitors have been reported to show synergistic/additive effects in preclinical studies. Because COX-2 and EGFR tyrosine kinase inhibitors are toxic as single agents in clinical trials, the combination of COX-2 and EGFR tyrosine kinase inhibitors used at lower doses seems more promising than monotherapy with either as a novel strategy in head and neck cancer chemoprevention.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
3 Department of Health and Human Services. NIH halts use of COX-2 inhibitor in large cancer prevention trial. NIH News, December 17, 2004. Available at http://www.nih.gov/news/pr/dec2004.
4 The Food and Drug Administration announces series of changes to the class of marketed nonsteroidal anti-inflammatory drugs. Food and Drug Administration News, April 7, 2005. Available at http://www.fda.gov/bbs/topics/news/2005.
Received 9/20/04; revised 7/13/05; accepted 7/15/05.
This article has been cited by other articles:
|
|
 |
|
  C. Oehler-Janne, F. Huguet, S. Provencher, B. Seifert, L. Negretti, M.-O. Riener, M. Bonet, A. S. Allal, and I. F. Ciernik HIV-Specific Differences in Outcome of Squamous Cell Carcinoma of the Anal Canal: A Multicentric Cohort Study of HIV-Positive Patients Receiving Highly Active Antiretroviral Therapy J. Clin. Oncol., May 20, 2008; 26(15): 2550 - 2557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L C Huber, P Kunzler, S H Boyce, B A Michel, R E Gay, B S Ink, and S Gay Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts Ann Rheum Dis, March 1, 2008; 67(3): 389 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. R. Khuri and D. M. Shin Head and Neck Cancer Chemoprevention Gets a Shot in the Arm J. Clin. Oncol., January 20, 2008; 26(3): 345 - 347. [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Sackett, I. Bairati, F. Meyer, E. Jobin, S. Lussier, A. Fortin, M. Gelinas, A. Nabid, F. Brochet, and B. Tetu Prognostic Significance of Cyclooxygenase-2 Overexpression in Glottic Cancer Clin. Cancer Res., January 1, 2008; 14(1): 67 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Choe, Z. Chen, C. M. Klass, X. Zhang, and D. M. Shin Enhancement of Docetaxel-Induced Cytotoxicity by Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways in Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., May 15, 2007; 13(10): 3015 - 3023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-C. SONG, S.-H. KIM, Y.-S. JUHNN, and Y.-S. SONG Apoptotic Effect of Celecoxib Dependent Upon p53 Status in Human Ovarian Cancer Cells Ann. N.Y. Acad. Sci., January 1, 2007; 1095(1): 26 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lippman and J. J. Lee Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res., March 15, 2006; 66(6): 2893 - 2903. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
